ஜர்னல் ஆஃப் கிளினிக்கல் எபிஜெனெடிக்ஸ் திறந்த அணுகல்

சுருக்கம்

Synergistic pharmacology: Targeting two epigenetic enzyme targets in a protein complex

Sriram Rajagopal Jubilant Drug Discovery and Development Center, India

Introduction:
Cancer patient treatment with single agent or single target modulation leads to poor clinical outcome. This is due to
tumor cell heterogeneity, pathway redundancy in cancer cells and presence of cancer stem cells that are difficult to
eradicate. In a clinical setting, drug cocktail is the preferred choice of treatment to address this but has its limitation.
Therefore targeting epigenetic pathways has the ability to modulate number of disease specific genes and offers the
opportunity to address multifactorial diseases. In this regard, a single small molecule inhibitor modulating two or more
disease relevant protein pathways overcome regulatory and developmental hurdles of cocktail drug development in a
clinical trial.
Conclusion: Hence, a targeted therapy with poly pharmacology will be beneficial and better tolerated for cancer
patients. Many epigenetic targets are over expressed in human cancer tissue as compared to normal tissue. Epigenetic
alterations of the genome are through the modification of the DNA/ histone proteins that lead to modulation of
oncogenes and tumor suppressor genes that regulate cancer specific processes. A histone modification influences the
recruitment of other epigenetic/ transcription factor proteins that in turn influence the gene expression. Understanding
the targets of such multi protein complex regulates gene expression can help in building targeted pharmacological
approaches leading to the design of compounds with better efficacy. In my presentation, I will cover our approach in
testing this hypothesis with few epigenetic targets and tool compounds using mechanistic studies and preclinical
models.
Recent Publications.
Jay H Kalin (2018) Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. Nature
Communication 9(1):53. 2. Perri F, et al. (2017) Epigenetic control of gene expression: Potential implications for
cancer treatment. Critical Reviews in Oncology/Hematology 111:166–172. 3. Po-Hsien Haung, et al. (2011) Histone
deacetylase inhibitors stimulate histone h3 lysine 4 methylation in part via transcriptional repression of histone h3
lysine 4 demethylases. Molecular Pharmacology 79(1):197–206